국가: 캐나다
언어: 영어
출처: Health Canada
ERYTHROMYCIN
STERI-MED PHARMA INC.
S01AA17
ERYTHROMYCIN
5MG
OINTMENT
ERYTHROMYCIN 5MG
OPHTHALMIC
3.5/1.0G
Prescription
ANTIBACTERIALS
Active ingredient group (AIG) number: 0105708019; AHFS:
APPROVED
2021-06-03
_ _ _ERYTHROMYCIN ophthalmic ointment USP _ _Prescribing Information _ _Page 1 of 6_ PRESCRIBING INFORMATION INCLUDING PATIENT MEDICATION INFORMATION Pr ERYTHROMYCIN OPHTHALMIC OINTMENT USP Erythromycin ophthalmic ointment USP 5mg / g ANTIBIOTIC Steri-Med Pharma Inc. 242 St-Cyrille Ouest Upton, Quebec, Canada J0H 2E0 Date of Revision: May 3, 2021 Submission Control No: 251871 _ _ _ERYTHROMYCIN ophthalmic ointment USP _ _Prescribing Information _ _Page 2 of 6_ PRESCRIBING INFORMATION Pr ERYTHROMYCIN OPHTHALMIC OINTMENT USP Erythromycin ophthalmic ointment USP 5mg / g THERAPEUTIC CLASSIFICATION Antibiotic ACTION AND CLINICAL PHARMACOLOGY Erythromycin inhibits protein synthesis by binding to the 50S ribosomal subunit within the microorganism. It is usually bacteriostatic but may be bactericidal depending on the sensitivity and number of organisms and the concentrations of the drug. Its spectrum of activity is similar to that of penicillin G. Resistance to erythromycin of some strains of _H. influenza_ and Staphylococci has been demonstrated. INDICATIONS For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to erythromycin. For prophylaxis of ophthalmic neonatorum due to _N. gonorrhoeae_ or _C. trachomatis_. The Canadian Pediatric Society, the Centers for Diseases Control and the Committee on Drugs (US), the Committee of Fetus and Newborn and the Committee on Infectious Diseases of the American Academy of Pediatrics recommend 1% silver nitrate solution in single dose ampoules or single use tubes of an ophthalmic ointment containing 0.5% erythromycin or 1% tetracycline as effective and acceptable regimens for prophylaxis of gonococcal ophthalmia neonatorum. Erythromycin ophthalmic ointment has also been effective for prevention of neonatal conjunctivitis due to _C. trachomatis_, a condition that may develop one to several weeks after delivery in infants of mothers whose birth canal harbor the organism. To reduce the development of drug-resistant bact 전체 문서 읽기